KR20210044233A - 흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명 - Google Patents

흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명 Download PDF

Info

Publication number
KR20210044233A
KR20210044233A KR1020217005548A KR20217005548A KR20210044233A KR 20210044233 A KR20210044233 A KR 20210044233A KR 1020217005548 A KR1020217005548 A KR 1020217005548A KR 20217005548 A KR20217005548 A KR 20217005548A KR 20210044233 A KR20210044233 A KR 20210044233A
Authority
KR
South Korea
Prior art keywords
gene expression
plat
gdf15
itgb3
sln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217005548A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 메베스
도메니코 벨로모
Original Assignee
스카이라인덱스 비.브이.
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스카이라인덱스 비.브이., 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 filed Critical 스카이라인덱스 비.브이.
Publication of KR20210044233A publication Critical patent/KR20210044233A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217005548A 2018-07-25 2019-07-25 흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명 Pending KR20210044233A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US62/703,221 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US62/750,294 2018-10-25
US201862778777P 2018-12-12 2018-12-12
US62/778,777 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (1)

Publication Number Publication Date
KR20210044233A true KR20210044233A (ko) 2021-04-22

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005548A Pending KR20210044233A (ko) 2018-07-25 2019-07-25 흑색종의 전이 및 환자의 예후를 예측하기 위한 유전자 서명

Country Status (11)

Country Link
US (2) US12473599B2 (https=)
EP (1) EP3827101B1 (https=)
JP (1) JP7633159B2 (https=)
KR (1) KR20210044233A (https=)
CN (1) CN113039289B (https=)
AU (1) AU2019310636B2 (https=)
CA (1) CA3107401A1 (https=)
DK (1) DK3827101T3 (https=)
ES (1) ES2966015T3 (https=)
IL (1) IL280377A (https=)
WO (1) WO2020022895A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230012710A (ko) * 2021-07-16 2023-01-26 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023107329A1 (en) * 2021-12-08 2023-06-15 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003298689A1 (en) 2002-11-21 2004-06-18 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
AU2007292219B2 (en) 2006-09-06 2014-04-24 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
AU2008247502A1 (en) 2007-05-04 2008-11-13 Dermtech International Diagnosis of melanoma by nucleic acid analysis
EP2191020A2 (en) 2007-08-16 2010-06-02 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
AU2009221778A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US20120128667A1 (en) 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
AU2011305696A1 (en) 2010-09-20 2013-05-02 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014077915A1 (en) 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2016025717A1 (en) * 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MX388345B (es) 2016-05-10 2025-03-19 Mayo Found Medical Education & Res Métodos y materiales para estadificar cáncer de piel y seleccionar tratamiento.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230012710A (ko) * 2021-07-16 2023-01-26 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군

Also Published As

Publication number Publication date
CN113039289A (zh) 2021-06-25
US12473599B2 (en) 2025-11-18
JP7633159B2 (ja) 2025-02-19
EP3827101B1 (en) 2023-11-08
WO2020022895A2 (en) 2020-01-30
NZ771988A (en) 2025-02-28
AU2019310636B2 (en) 2025-06-26
DK3827101T3 (da) 2023-12-11
EP3827101A2 (en) 2021-06-02
IL280377A (en) 2021-03-25
ES2966015T3 (es) 2024-04-17
US20260071281A1 (en) 2026-03-12
WO2020022895A3 (en) 2020-04-02
CA3107401A1 (en) 2020-01-30
US20210301353A1 (en) 2021-09-30
JP2021531831A (ja) 2021-11-25
CN113039289B (zh) 2025-11-07
AU2019310636A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20260071281A1 (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
US20060199210A1 (en) Methods and kits for monitoring Barrett's metaplasia
AU2019263297B2 (en) Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma
AU2022204690A1 (en) Methods For Predicting Risk Of Metastasis In Cutaneous Melanoma
KR101860238B1 (ko) 신장암 예후 진단 마커로서 zfp28, fam155a 및 dpp6의 용도
AU2021214252A1 (en) Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma
CN116936086A (zh) 乳腺癌远端转移风险预测基因模型的建构方法和风险预测方法
CN111315897B (zh) 用于黑素瘤检测的方法
JP2022512634A (ja) Ｐｄｅ４ｄ７及びｄｈｘ９発現に基づく術前のリスク層別化
CN110387423A (zh) 前庭神经鞘瘤诊断用生物标志物
AU2021325154A1 (en) Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma
JP2021519070A (ja) Ｔｍｐｒｓｓ２−ｅｒｇ融合状態により選択された、ｐｄｅ４ｄ変異発現、及び術後の臨床変数に基づく、術後リスクの層別化
HK40046957B (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
HK40046957A (en) Gene signatures for predicting metastasis of melanoma and patient prognosis
CN116926190A (zh) 测量乳腺癌远端转移风险的预后标志物及其应用
WO2022031670A1 (en) Methods of diagnosing and treating patients with pigmented skin lesions
CN117004711A (zh) 测量乳腺癌局部复发风险的预后标志物的工具及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701